Bimzelx Side Effects
Generic name: bimekizumab
Medically reviewed by Drugs.com. Last updated on Oct 17, 2023.
Note: This document contains side effect information about bimekizumab. Some dosage forms listed on this page may not apply to the brand name Bimzelx.
Applies to bimekizumab: subcutaneous solution.
Serious side effects of Bimzelx
Along with its needed effects, bimekizumab (the active ingredient contained in Bimzelx) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking bimekizumab:
More common
- Body aches or pain
- chest tightness
- chills
- cough
- dryness or soreness of the throat
- ear congestion
- fever
- headache
- hoarseness
- loss of voice
- muscle aches
- pain or tenderness around eyes and cheekbones
- sneezing
- sore mouth or tongue
- stuffy or runny nose
- tender, swollen glands in the neck
- trouble breathing
- trouble in swallowing
- unusual tiredness or weakness
- white patches in the mouth or on the tongue
Less common
- Burning or stinging of the skin
- diarrhea
- itching in the genital or other skin areas
- itching of the vagina or genitals
- loss of appetite
- nausea
- painful cold sores or blisters on the lips, nose, eyes, or genitals
- scaling
- stomach pain
- thick, white vaginal discharge with mild or no odor
Incidence not known
- Changes in behavior
- dark urine
- rectal bleeding
- thoughts of killing oneself
- vomiting
- yellow eyes or skin
Other side effects of Bimzelx
Some side effects of bimekizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
- Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- blemishes on the skin
- burning, itching, and pain in hairy areas, pus at the root of hair
- pimples
For Healthcare Professionals
Applies to bimekizumab: subcutaneous injection.
General
Upper respiratory infections were the most frequently reported adverse reactions, including nasopharyngitis and oral candidiasis.[Ref]
Dermatologic
Tinea Infections included tinea pedis, fungal skin infection, tinea versicolor, tinea cruris, tinea infection, body tinea, and onychomycosis[Ref]
Common (1% to 10%): Acne, folliculitis, rash, tinea infections, dermatitis, eczema, herpes simplex
Uncommon (0.1% to 1%): Dermatitis contact, dyshidrotic eczema, intertrigo[Ref]
Gastrointestinal
Common (1% to 10%): Oral candidiasis, oropharyngeal candidiasis, gastroenteritis, oral herpes
Uncommon (0.1% to 1%): Inflammatory bowel disease, mucosal, and cutaneous candidiasis[Ref]
Oral candidiasis included oropharyngeal candidiasis, oral fungal infection, fungal pharyngitis, and fungal oropharyngitis.
Gastroenteritis included enterovirus infection, gastroenteritis bacterial, and gastroenteritis viral.[Ref]
Hematologic
Uncommon (0.1% to 1%): Neutropenia[Ref]
Hepatic
Common (1% to 10%): Elevated liver enzymes[Ref]
Hypersensitivity
Frequency not reported: Hypersensitivity reactions including anaphylactic reactions[Ref]
Immunologic
Very common (10% or more): Anti-drug antibodies (up to 45%)[Ref]
Local
Injection site reactions included injection site erythema, injection site edema, injection site pain, injection site bruising, and injection site swelling.[Ref]
Common (1% to 10%): Injection site reactions[Ref]
Nervous system
Common (1% to 10%): Headache[Ref]
Ocular
Uncommon (0.1% to 1%): Conjunctivitis[Ref]
Other
Other candida infections included vulvovaginal candidiasis, vulvovaginal mycotic infection, skin candida, and genital candidiasis.[Ref]
Common (1% to 10%): Fatigue
Uncommon (0.1% to 1%): Otitis externa, otitis media, other candida infections[Ref]
Respiratory
Very common (10% or more): Upper respiratory tract infection (up to 15%)[Ref]
Upper respiratory tract infections included nasopharyngitis, pharyngitis, rhinitis, viral upper respiratory tract infection, sinusitis, tonsillitis, pharyngitis streptococcal, pharyngitis bacterial, viral rhinitis, influenza, and peritonsillar abscess.[Ref]
Psychiatric
Common (1% to 10%): Passive suicidal ideation, completed suicide, attempted suicide[Ref]
More about Bimzelx (bimekizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
References
1. Product Information. Bimzelx (bimekizumab). UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia. 2023.
2. Product Information. Bimzelx (bimekizumab). UCB Pharma Ltd. 2023.
3. Product Information. Bimzelx Prefilled Syringe (bimekizumab). UCB Pharma Inc. 2023.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.